Showing 2071-2080 of 3223 results for "".
- The FDA Does Not Approve Allergan’s Wet AMD Drug Candidate Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol/2477937/Citing an unfavorable benefit-risk ratio, the FDA rejected Allergan and co-developer Molecular Partners’ wet AMD drug candidate Abicipar pegol. The FDA issued a complete response letter to the biologics license application (BLA) for Abicipar pegol, a novel, investigational DARPin the
- Saunders Finds Life After Allergan on Board at Newly IPO’ed BridgeBiohttps://modernod.com/news/saunders-finds-life-after-allergan-on-board-at-newly-ipoed-bridgebio/2477933/Less than 2 months after Allergan was officially taken in by AbbVie, its last helmsman, Brent Saunders, has landed on the board of a young biotech that recently pulled off a large IPO, according to a FiercePharma
- US Sues Regeneron Over Alleged Kickbacks for Eyleahttps://modernod.com/news/us-sues-regeneron-over-alleged-kickbacks-for-eylea/2477932/The US Attorney for the District of Massachusetts announced on Wednesday that the government filed a civil complaint against Regeneron Pharmaceuticals, alleging that the drugmaker paid $35 million in kickbacks for Eylea (aflibercept), using a foundation as a conduit to cover co-pays for the VEGF
- Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Programhttps://modernod.com/news/aldeyra-therapeutics-receives-orphan-medicinal-product-designation-from-the-european-commission-for-adx-2191-retinal-disease-program/2477898/Aldeyra Therapeutics announced that ADX-2191 has been designated an orphan medicinal product by the European Commission for the treatment of retinal detachment. ADX-2191 is an investigational therapy in clinical development in the U.S. for the prevention of proliferative vitreoretinopathy (PVR),
- US States Sue 26 Generic Drugmakers for Alleged Price Fixinghttps://modernod.com/news/us-states-sue-26-generic-drugmakers-for-alleged-price-fixing/2479522/A coalition of 51 US states and territories filed a lawsuit in federal court in Connecticut on Wednesday, accusing 26 drug companies, including Taro, Perrigo, Novartis’ Sandoz unit, Actavis, Mylan, Teva, G&W and Glenmark, of conspiring to fix prices and allocate markets for at least 80
- New Alcon Program Aims to Help ECPs Tap Into Opportunities in the Dry Eye Market Amid COVID-19 Crisishttps://modernod.com/news/new-alcon-program-aims-to-help-ecps-tap-into-opportunities-in-the-dry-eye-market-amid-covid-19-crisis/2477838/Alcon has launched a new program called “No Reason to Wait: Success Starts Now” aimed at helping eye care professionals (ECPs) better understand the practice and patient benefits of treating the root cause of evaporat
- Aldeyra Therapeutics Advances Investigational HSP90 Inhibitor to Clinical Testing for COVID-19https://modernod.com/news/aldeyra-therapeutics-advances-ivestigational-hsp90-inhibitor-to-clinical-testing-for-covid-19/2477799/Aldeyra Therapeutics, which has several drug candidates for the treatment of ocular inflammatory diseases, announced the planned advancement of the investigational new HSP90 inhibitor ADX-1612 to clinical testing for COVID-19, and provided an update on ADX-629, a novel investigational RASP inhibi
- Kubota Vision Introduces Electronic Eyeglasses to Stop Myopia in Childrenhttps://modernod.com/news/kubota-vision-introduces-electronic-eyeglasses-to-stop-myopia-in-children/2477794/Kubota Vision announced positive clinical results from myopia control tests in humans. Utilizing electronic tabletop optical projection devices that embody Kubota Glasses technology, myopically-defocused images were projected on the peripheral retina of subjects to study if progression of myopia
- Allergan to Share New Safety and Efficacy Data on Recently Approved Durysta at ASCRS Virtual Meetinghttps://modernod.com/news/allergan-to-share-new-safety-and-efficacy-data-on-recently-approved-durysta-at-ascrs-virtual-meeting/2477773/Allergan, which is now part of AbbVie, will present new glaucoma research at the American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting on May 16. Data will include four virtual paper presentations analyzing safety and efficacy across several subgroups from the phase 3
- Artificial Intelligence Algorithm Can Rapidly Detect Severity of Common Blinding Eye Diseasehttps://modernod.com/news/artificial-intelligence-algorithm-can-rapidly-detect-severity-of-common-blinding-eye-disease/2477752/A new artificial intelligence (AI) algorithm developed by researchers at New York Eye and Ear Infirmary of Mount Sinai (NYEE) can rapidly and accurately detect age-related macular degeneration (AMD), according to a company news release. The study, published in the April/May issue of Tr